Srilatha Edupuganti

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/749700/publications.pdf

Version: 2024-02-01

44	4,529	361413	289244
papers	citations	20 h-index	40 g-index

47	47	47	11252
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Occupational risk factors for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection among healthcare personnel: A cross-sectional analysis of subjects enrolled in the COVID-19 Prevention in Emory Healthcare Personnel (COPE) study. Infection Control and Hospital Epidemiology, 2022, 43, 381-386.	1.8	10
2	Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants. Human Vaccines and Immunotherapeutics, 2022, 18, 1-10.	3.3	6
3	Occupational risk factors for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection among healthcare personnel: A 6-month prospective analysis of the COVID-19 Prevention in Emory Healthcare Personnel (COPE) Study. Infection Control and Hospital Epidemiology, 2022, , 1-8.	1.8	7
4	EVITA Dengue: a cluster-randomized controlled trial to EValuate the efficacy of Wolbachia-InfecTed Aedes aegypti mosquitoes in reducing the incidence of Arboviral infection in Brazil. Trials, 2022, 23, 185.	1.6	5
5	Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial. Lancet Infectious Diseases, The, 2022, 22, 1210-1220.	9.1	15
6	Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant. Journal of Clinical Oncology, 2022, 40, 3808-3816.	1.6	19
7	Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials. EBioMedicine, 2021, 64, 103203.	6.1	14
8	Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. Cell Host and Microbe, 2021, 29, 516-521.e3.	11.0	199
9	Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 87, 671-679.	2.1	16
10	A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline Findings. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 87, 680-687.	2.1	25
11	Effect of Monoclonal Antibody Treatment on Clinical Outcomes in Ambulatory Patients With Coronavirus Disease 2019. Open Forum Infectious Diseases, 2021, 8, ofab315.	0.9	12
12	Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and TÂcells. Cell Reports Medicine, 2021, 2, 100354.	6.5	316
13	Evaluation of a SARS-CoV-2 Capture IgM Antibody Assay in Convalescent Sera. Microbiology Spectrum, 2021, 9, e0045821.	3.0	3
14	Application of SARS-CoV-2 Serology to Address Public Health Priorities. Frontiers in Public Health, 2021, 9, 744535.	2.7	4
15	Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study. Lancet HIV,the, 2020, 7, e688-e698.	4.7	58
16	Duration of Cellular and Humoral Responses after Quadrivalent Human Papillomavirus Vaccination in Healthy Female Adults with or without Prior Type 16 and/or 18 Exposure. Vaccines, 2020, 8, 348.	4.4	4
17	Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. Science, 2020, 369, 1210-1220.	12.6	947
18	COVID-19 Serology at Population Scale: SARS-CoV-2-Specific Antibody Responses in Saliva. Journal of Clinical Microbiology, 2020, 59, .	3.9	193

#	Article	IF	Citations
19	Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C). Pediatrics, 2020, 146, .	2.1	113
20	Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GPÂ® DNA Vaccine and IL-12 Is Safe, Tolerable, Acceptable in Healthy Adults. Vaccines, 2020, 8, 741.	4.4	11
21	The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Science Immunology, 2020, 5, .	11.9	772
22	Baseline Levels of Influenza-Specific B Cells and T Cell Responses Modulate Human Immune Responses to Swine Variant Influenza A/H3N2 Vaccine. Vaccines, 2020, 8, 126.	4.4	1
23	Robust antibody and cellular responses induced by DNA-only vaccination for HIV. JCI Insight, 2020, 5, .	5.0	25
24	Decreased humoral immunity to mumps in young adults immunized with MMR vaccine in childhood. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 19071-19076.	7.1	30
25	Clinical, Virologic, and Immunologic Characteristics of Zika Virus Infection in a Cohort of US Patients: Prolonged RNA Detection in Whole Blood. Open Forum Infectious Diseases, 2019, 6, ofy352.	0.9	26
26	1272. Feasibility and Successful Enrollment in Proof-of-Concept Trials to Assess Safety and Efficacy of a Broadly Neutralizing Monoclonal Antibody, VRC01, to Prevent HIV-1 Acquisitionin in Uninfected Individuals. Open Forum Infectious Diseases, 2019, 6, S457-S458.	0.9	0
27	Innate, T-, and B-Cell Responses in Acute Human Zika Patients. Clinical Infectious Diseases, 2018, 66, 1-10.	5.8	162
28	2492. Clinical, Virologic, and Immunologic Characteristics of Zika Virus Infection in a Cohort of US Patients. Open Forum Infectious Diseases, 2018, 5, S748-S748.	0.9	0
29	Tularemia vaccine: Safety, reactogenicity, â€œTakeâ€•skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain â€“ A phase 2 randomized clinical Trial. Vaccine, 2017, 35, 4730-4737.	3.8	30
30	Origin and differentiation of human memory CD8 T cells after vaccination. Nature, 2017, 552, 362-367.	27.8	412
31	Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. Statistical Communications in Infectious Diseases, 2017, 9, .	0.2	62
32	Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 7852-7857.	7.1	479
33	Recognition of influenza H3N2 variant virus by human neutralizing antibodies. JCI Insight, 2016, 1, .	5.0	20
34	DNA Priming for Seasonal Influenza Vaccine: A Phase 1b Double-Blind Randomized Clinical Trial. PLoS ONE, 2015, 10, e0125914.	2.5	17
35	Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons â‰¥18 Years Old. Journal of Infectious Diseases, 2015, 212, 552-561.	4.0	11
36	Initial viral load determines the magnitude of the human CD8 T cell response to yellow fever vaccination. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 3050-3055.	7.1	111

#	Article	IF	Citations
37	Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naÃ¯ve subjects. Vaccine, 2015, 33, 5225-5234.	3.8	92
38	Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009â€“2010 seasonal trivalent influenza vaccinations. Vaccine, 2015, 33, 163-173.	3.8	3
39	LB-2Avian Influenza A/H7N9 Vaccine Mixed with MF59 Adjuvant at the Point-of-Use. A Randomized Clinical Trial of a Pandemic Threat Response. Open Forum Infectious Diseases, 2014, 1, S66-S67.	0.9	0
40	Serological Responses to an Avian Influenza A/H7N9 Vaccine Mixed at the Point-of-Use With MF59 Adjuvant. JAMA - Journal of the American Medical Association, 2014, 312, 1409.	7.4	126
41	A Randomized, Double-Blind, Controlled Trial of the 17D Yellow Fever Virus Vaccine Given in Combination with Immune Globulin or Placebo: Comparative Viremia and Immunogenicity. American Journal of Tropical Medicine and Hygiene, 2013, 88, 172-177.	1.4	27
42	Enrollment in YFV Vaccine Trial: An Evaluation of Recruitment Outcomes Associated with a Randomized Controlled Double-Blind Trial of a Live Attenuated Yellow Fever Vaccine. Tropical Medicine & Surgery, 2013, 1, 117.	0.1	2
43	Fusarium falciforme Vertebral Abscess and Osteomyelitis: Case Report and Molecular Classification. Journal of Clinical Microbiology, 2011, 49, 2350-2353.	3.9	21
44	Cytotoxic T-Lymphocyte Responses to Canarypox Vector-Based HIV Vaccines in HIV-Seronegative Individuals: A Meta-analysis of Published Studies. HIV Clinical Trials, 2004, 5, 259-268.	2.0	12